Spectrum Therapeutics provides update on its global clinical research program and unveils pharmacovigilance program

Spectrum Therapeutics (“Spectrum”), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the “Company” or “Canopy Growth”) is pleased to share an update on its efforts to develop and commercialize validated cannabis medicines through clinical trials. Demand for cannabinoid-based medicines is emerging around the world. With a highly experienced scientific team and the resources needed to conduct robust clinical trials, Spectrum Therapeutics is pursuing research to introduce products for the therapeutic areas of pain, mood and sleep and to gain access to new markets independent of medical cannabis laws.

Related posts

SOL Global Portfolio Company Heavenly Rx Announces Key Leadership Appointments

CCT IMPACT Agent

4Front Secures $50M Loan to Fund Real Estate-Related Development

CCT IMPACT Agent

SADIS & GOLDBERG Formalizes Practice Group for Clients Navigating the Cannabis Industry

CCT IMPACT Agent

Leave a Comment